Cutler Group LP Intellia Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 01, 2023	SELL	$33.3 - $44.82 $9,990 - $13,446	-300 Reduced 75.0%	100 $0
Q4 2022 Feb 07, 2023	SELL	$33.21 - $62.69 $6,642 - $12,538	-200 Reduced 33.33%	400 $0
Q3 2022 Oct 25, 2022	BUY	$53.92 - $71.7 $10,784 - $14,340	200 Added 50.0%	600 $0
Q2 2022 Aug 04, 2022	SELL	$38.49 - $76.21 $7,698 - $15,241	-200 Reduced 33.33%	400 $1,000
Q1 2022 Apr 14, 2022	BUY	$58.27 - $118.99 $29,135 - $59,495	500 Added 500.0%	600 $4,000
Q4 2021 Jan 18, 2022	SELL	$100.76 - $138.36 $110,836 - $152,196	-1,100 Reduced 91.67%	100 $0
Q3 2021 Oct 26, 2021	SELL	$132.37 - $176.78 $1.13 Million - $1.5 Million	-8,500 Reduced 87.63%	1,200 $9,000
Q2 2021 Jul 19, 2021	BUY	$60.88 - $161.91 $590,536 - $1.57 Million	9,700 New	9,700 $271,000
Q3 2018 Nov 07, 2018	SELL	$25.78 - $32.6 $2,578 - $3,260	-100 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$20.02 - $30.79 $2,002 - $3,079	-100 Reduced 50.0%	100 $0
Q1 2018 May 11, 2018	SELL	$19.43 - $34.95 $106,865 - $192,225	-5,500 Reduced 96.49%	200 $0
Q4 2017 Jan 17, 2018	BUY	$17.39 - $31.12 $12,173 - $21,784	700 Added 14.0%	5,700 $11,000
Q3 2017 Oct 17, 2017	BUY	$15.16 - $25.75 $75,800 - $128,750	5,000	5,000 $39,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $775M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.